About Us

We are a team of scientists and biotech industry veterans focused on realizing the potential of one of nature’s more highly-conserved neuropeptides

About Protagenic

Protagenic Therapeutics (PTIX) is a New York-based biotechnology company developing a platform of first-in-class treatments for stress-related disorders like PTSD, depression, anxiety, and drug & alcohol addiction. These disorders are growing in prevalence, and are lacking safe, effective treatments for millions of sufferers globally. For decades, scientists and clinicians have documented the association with and impact of stress in these disease states (see “Stress Feedback Loop”). Protagenics’ lead compound (PT00114) taps into a brain system that counteracts stress overdrive at a cellular level in the brain, helping break the vicious cycle of stress leading to psychological and physical harm and further sensitivity to stress.

Leadership Team

Garo Black

Garo H. Armen, Ph.D.

Executive Chairman

Andrew Slee, Ph.D.

Chief Operating Officer
Robert Stein

Robert B. Stein, MD, Ph.D.

Chief Medical Officer
Alexander K. Arrow, MD, CFA

Alexander K. Arrow, MD, CFA

Chief Financial Officer

Board of Directors

Garo Black

Garo H. Armen, Ph.D.

Executive Chairman
Brian Corvese

Brian J. Corvese

DIRECTOR
Robert Stein

Robert B. Stein, MD, Ph.D.

Chief Medical Officer
Joshua Silverman

Joshua Silverman

Director
Khalil Barrage

Khalil Barrage

DIRECTOR
Jennifer Black

Jennifer Buell, PhD.

Director

Scientific Advisors

David Lovejoy

David Lovejoy, Ph.D.

Scientific Advisor
Dalia Barsyte

Dalia Barsyte, Ph.D.

Scientific Advisor

© 2021 Protagenic Therapeutics, Inc.